Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Sökning: onr:"swepub:oai:lup.lub.lu.se:288b5555-1eb4-4530-87c6-9ed6cab0864d" > Results of a random...

1 av 1
Föregående post
Nästa post
Till träfflistan

Hugosson, Jonas,1955Gothenburg University,Göteborgs universitet,Institutionen för de kirurgiska disciplinerna, Avdelningen för urologi,Institute of Surgical Sciences, Department of Urology (författare)

Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma

Artikel/kapitelEngelska2004

Förlag, utgivningsår, omfång ...

2004
Wiley,2004

Nummerbeteckningar

LIBRIS-ID:oai:lup.lub.lu.se:288b5555-1eb4-4530-87c6-9ed6cab0864d
https://lup.lub.lu.se/record/284716URI
https://doi.org/10.1002/cncr.20126DOI
https://gup.ub.gu.se/publication/42626URI

Kompletterande språkuppgifter

Språk:engelska
Sammanfattning på:engelska

Ingår i deldatabas

SwePubSwePub

Klassifikation

Ämneskategori:art swepub-publicationtype
Ämneskategori:ref swepub-contenttype

Anmärkningar

BACKGROUND. The purpose of the current study was to evaluate the effectiveness of a prostate carcinoma screening program in which serum prostate-specific antigen (PSA) levels were measured. METHODS. From a group of 20,000 men born between January 1, 1930, and December 31, 1944, 10,000 men were randomized into a screening group and 10,000 were randomized into a control group. Patients in the screening group were invited to undergo initial PSA testing between 1995 and 1996 and then were invited to receive testing every second year thereafter for 8 years (for a total of 4 PSA tests). 2 Men with PSA levels greater than or equal to 3 ng/mL (or greater than or equal to 2.54 ng/mL, in the third and fourth screening rounds) were invited to undergo clinical investigation, which included sextant 3 biopsy of the prostate. By linking to the regional cancer registry, the authors were able to obtain the true and expected incidence rates for the screening and control groups. RESULTS. The screening participation rate was high (73%). A total of 884 malignancies have been detected to date, with 640 having been detected in the screening group. There was an early and marked shift toward more favorable disease stage and grade for malignancies detected on repeat screening. In the fourth screening round, only 2 of 82 detected malignancies were classified as advanced disease. Of the 227 screen-detected tumors on which surgery was performed, only 20 (8.8%) had small volume (< 0.2 cm(3)). Forty-three interval malignancies were detected, but only five were accompanied by symptoms. At 8 years, the cumulative disease incidence rate among screening participants was 7.3%, compared with 2.4% in the control arm. The incidence rate observed in the screening population corresponds to the cumulative incidence rate observed in the Swedish male population at age 72 years. CONCLUSIONS. Biennial PSA screening was very successful in diagnosing prostate carcinoma at an early stage, when curative treatment typically is effective. In addition, the results regarding interval malignancies were favorable. Thus, decreased mortality should be observed on long-term follow-up. The lead time associated with screening appears to fall within the range described in earlier studies involving frozen sera (i.e., 5-9 years).

Ämnesord och genrebeteckningar

MEDICIN OCH HÄLSOVETENSKAP Klinisk medicin Cancer och onkologi hsv//swe
MEDICAL AND HEALTH SCIENCES Clinical Medicine Cancer and Oncology hsv//eng
MEDICIN OCH HÄLSOVETENSKAP Klinisk medicin Urologi och njurmedicin hsv//swe
MEDICAL AND HEALTH SCIENCES Clinical Medicine Urology and Nephrology hsv//eng
screening
early detection
prostate-specific antigen
prostate carcinoma
treatment
epidemiology
prostate-specific antigen • prostate carcinoma • early detection • screening • treatment • epidemiology

Biuppslag (personer, institutioner, konferenser, titlar ...)

Aus, GGothenburg University,Göteborgs universitet,Institutionen för de kirurgiska disciplinerna, Avdelningen för urologi,Institute of Surgical Sciences, Department of Urology (författare)
Lilja, HansLund University,Lunds universitet,Klinisk kemi, Malmö,Forskargrupper vid Lunds universitet,Clinical Chemistry, Malmö,Lund University Research Groups(Swepub:lu)klke-hli (författare)
Lodding, PGothenburg University,Göteborgs universitet,Institutionen för de kirurgiska disciplinerna, Avdelningen för urologi,Institute of Surgical Sciences, Department of Urology (författare)
Pihl, CG (författare)
Göteborgs universitetInstitutionen för de kirurgiska disciplinerna, Avdelningen för urologi (creator_code:org_t)

Sammanhörande titlar

Ingår i:Cancer: Wiley100:7, s. 1397-14051097-01420008-543X

Internetlänk

Hitta via bibliotek

Cancer (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

1 av 1
Föregående post
Nästa post
Till träfflistan

Hitta mer i SwePub

Av författaren/redakt...: Hugosson, Jonas, ...; Aus, G; Lilja, Hans; Lodding, P; Pihl, CG

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Cancer och onkol ...

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Urologi och njur ...

Artiklar i publikationen: Cancer

Av lärosätet: Lunds universitet; Göteborgs universitet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se